Exploring the activity of pseudoephedrine in treating retrograde ejaculation following retroperitoneal lymph node dissection (RPLND) in survivors of testicular cancer - Part A
- Conditions
- Testicular cancerRetroperitoneal lymph node dissectionCancer - TesticularSurgery - Other surgery
- Registration Number
- ACTRN12622000537752
- Lead Sponsor
- Peter MacCallum Cancer Centre
- Brief Summary
n/a
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 52
Participants must meet all the following criteria for study entry:
1.Participant has provided written, informed consent OR electronic, informed consent sighted by an investigator, on Telehealth.
2.Males greater than or equal to 18 years at time of informed consent.
3.Histologically confirmed testicular germ cell tumour (based on archival tissue report)
4.Retroperitoneal lymph node dissection for management of testicular cancer at least six months prior to consent.
5.Participant is willing and able to comply with the protocol for the duration of the study including treatment, and scheduled visits and examination including follow up.
Participants who meet any of the following criteria will be excluded from study entry:
1.Currently receiving treatment or planning to receive treatment within two months (i.e., surgery, chemotherapy, radiotherapy) for testicular cancer (or other malignancy).
2.Known medical condition or other issue that in the opinion of the investigator, that would affect adherence to study requirements.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of retrograde ejaculation in participants receiving clinical follow-up following retroperitoneal lymph node dissection as assessed by patient report in supplementary questions (designed for PREPARE).[At enrolment.]
- Secondary Outcome Measures
Name Time Method